Нова Зеландия - английски - Medsafe (Medicines Safety Authority)

upjohn new zealand ulc - ziprasidone mesilate 40.93mg equivalent to 30 mg ziprasidone - powder for injection - 20 mg/ml - active: ziprasidone mesilate 40.93mg equivalent to 30 mg ziprasidone excipient: sulfobutyl betadex sodium water for injection

Нова Зеландия - английски - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - dextromethorphan hydrobromide monohydrate 10.5mg - pastille - 10.5 mg - active: dextromethorphan hydrobromide monohydrate 10.5mg excipient: acacia betadex citric acid limette flavour 18635/02 honey flavour 8366/001 levomenthol light liquid paraffin maltitol purified water quinoline yellow saccharin sodium sodium cyclamate white beeswax - bisolvon dry pastilles are used for the symptomatic treatment of dry, irritant, unproductive coughs.

Австралия - английски - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - ziprasidone mesilate, quantity: 27.29 mg (equivalent: ziprasidone, qty 20 mg) - injection, powder for - excipient ingredients: sulfobutyl betadex sodium - acute control and short-term management of agitation and disturbed behaviours in patients with schizophrenia and related psychoses when oral therapy is not appropriate.

Австралия - английски - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - itraconazole, quantity: 10 mg/ml - oral liquid, solution - excipient ingredients: propylene glycol; hydroxypropylbetadex; saccharin sodium; purified water; caramel; sorbitol solution (70 per cent) (non-crystallising); sodium hydroxide; hydrochloric acid; flavour - sporanox oral solution is indicated for: * the treatment of oral and/or oesophageal candidiasis in hiv-positive or other immunocompromised patients. * prophylaxis of fungal infections in neutropenic patients.

Австралия - английски - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - voriconazole, quantity: 200 mg - solution, powder for - excipient ingredients: hydroxypropylbetadex; hydrochloric acid; sodium chloride - voriconazole is indicated for treatment of the following fungal infections:,- invasive aspergillosis.,- serious candida infections (including c. krusei), including oesophageal and systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia).,- serious fungal infections caused by scedosporium spp. and fusarium spp.,- other serious fungal infections, in patients intolerant of, or refractory to, other therapy.,- prophylaxis in patients who are at high risk of developing invasive fungal infections. the indication is based on studies including patients undergoing haematopoietic stem cell transplantation.

Ирландия - английски - HPRA (Health Products Regulatory Authority)

bayer limited - ethinylestradiol (as betadex-clathrate) drospirenone - film coated tablet - 0.020+3.00 milligram

Ирландия - английски - HPRA (Health Products Regulatory Authority)

chiesi limited - piroxicam betadex - tablets effervescent - 20mg milligram

Нова Зеландия - английски - Medsafe (Medicines Safety Authority)

bayer new zealand limited - drospirenone 3mg; ethinylestradiol betadex clathrate 0.02mg (ethinylestradiol betadex clathrade amount equivalent ethinylestradiol 0.02mg) - film coated tablet - active: drospirenone 3mg ethinylestradiol betadex clathrate 0.02mg (ethinylestradiol betadex clathrade amount equivalent ethinylestradiol 0.02mg) excipient: hypromellose iron oxide red lactose monohydrate magnesium stearate maize starch purified talc titanium dioxide - yaz flex is indicated for use as: - an oral contraceptive - treatment of moderate acne vulgaris is women who seek oral contraception - treatment of symptoms of premenstrual dysphoric disorder (pmdd) in women who have chosen oral contraceptives as their method of birth control.

Нова Зеландия - английски - Medsafe (Medicines Safety Authority)

bayer new zealand limited - drospirenone 3mg (micronised); ethinylestradiol 30ug (present as betadex clathrate, micronised); levomefolate calcium 451ug equivalent to folic acid 400 µg, micronised; levomefolate calcium 451ug equivalent to folic acid 400 µg - tablet - 30µg/ 3mg/ 451µg - active: drospirenone 3mg (micronised) ethinylestradiol 30ug (present as betadex clathrate, micronised) levomefolate calcium 451ug equivalent to folic acid 400 µg, micronised excipient: croscarmellose sodium hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose opadry orange 02f32738 active: levomefolate calcium 451ug equivalent to folic acid 400 µg excipient: croscarmellose sodium hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose opadry pink 02f32737 - yasmin plus is indicated for women who choose to use an oral contraceptive as their method of contraception to raise folate levels for the purpose of reducing the risk of a neural tube defect in a pregnancy conceived while taking the product or shortly after discontinuing the product.

Нова Зеландия - английски - Medsafe (Medicines Safety Authority)

bayer new zealand limited - drospirenone 3mg (micronised); ethinylestradiol betadex clathrate 0.02mg (ethinylestradiol betadex clathrade amount equivalent ethinylestradiol 0.02mg); levomefolate calcium 0.451mg (micronised); levomefolate calcium 0.451mg (micronised) - film coated tablet - 3mg/0.02mg/0.451mg - active: drospirenone 3mg (micronised) ethinylestradiol betadex clathrate 0.02mg (ethinylestradiol betadex clathrade amount equivalent ethinylestradiol 0.02mg) levomefolate calcium 0.451mg (micronised) excipient: croscarmellose sodium hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose opadry pink active: levomefolate calcium 0.451mg (micronised) excipient: croscarmellose sodium hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose opadry pink 02f32737 - an oral contraceptive · oral contraception in women seeking to improve folate levels whilst taking oral contraception